Safety, tolerability, pharmacokinetics, and pharmacodynamics of SHR-2010, a novel anti-MASP-2 antibody, in healthy volunteers: a randomized, double-blind, placebo-controlled phase 1 study

This first-in-human study assessed the safety, tolerability, pharmacokinetics, and pharmacodynamics of SHR-2010, a novel humanized IgG4 monoclonal antibody targeting mannan-binding lectin serine protease-2, in healthy adults. In this randomized, double-blind, phase 1 study, eligible participants were randomly assigned to single ascending doses of SHR-2010 or placebo (32 via intravenous drip: 6:2; 0.3, 1.5, 4.0, and 8.0 mg/kg; 29 via subcutaneous injection: 8:2; 4.0, 8.0, and 12.0 mg/kg). The primary endpoints were safety and tolerability. SHR-2010 was well tolerated. Treatment-related adverse events (TRAEs) were similar in SHR-2010 groups (55.3% [26/47]) and placebo groups (78.6% [11/14]). No deaths or severe TRAEs were reported. In the intravenous dose groups, the C_max increased proportionally with the dose, while the AUC increased slightly more than the dose increment. In the subcutaneous injection groups, C_max and AUC demonstrated a linear relationship with dose. SHR-2010 demonstrated a notable inhibitory effect on lectin pathway, with the mean maximum inhibition rates exceeding 80.0% across the tested doses, compared to 6.7% with placebo. SHR-2010 was safe and well tolerated after a single dose and exhibited robust blockade of the lectin pathway, supporting further development. The trial is registered at ClinicalTrials.gov (NCT05398510).